2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol

Sidney C. Smith, Scott M Grundy

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines recently issued the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. This new guideline endorses a paradigm shift in strategies for reducing atherosclerotic cardiovascular disease (ASCVD) events by lowering blood cholesterol. Whereas previous guidelines focused on therapy to decrease low-density lipoprotein and non-high-density lipoprotein cholesterol to specific target levels, the new guideline instead proposes implementation of cholesterol-lowering treatment using evidenced-based intensity of statin therapy without such targets. The guideline also provides a new risk estimator for primary prevention decisions, including stroke outcomes and data on African Americans, which will significantly increase the number of patients recommended for outcome-related benefits of cholesterol-lowering therapy. The first section of this paper reviews the process by which the task force developed the new evidence-based guideline, the major findings and recommendations, and their implications. The second section primarily focuses on the question of how much low-density lipoprotein cholesterol should be lowered and on additional considerations in risk assessment.

Original languageEnglish (US)
Pages (from-to)601-612
Number of pages12
JournalJournal of the American College of Cardiology
Volume64
Issue number6
DOIs
StatePublished - Aug 12 2014

Fingerprint

American Heart Association
Cardiology
Cholesterol
Guidelines
Advisory Committees
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
LDL Lipoproteins
Practice Guidelines
African Americans
LDL Cholesterol
Cardiovascular Diseases
Stroke

Keywords

  • atherosclerosis
  • cardiovascular diseases
  • cholesterol
  • hydroxymethylglutaryl- CoA reductase inhibitors
  • LDL
  • lipoproteins
  • risk assessment
  • risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. / Smith, Sidney C.; Grundy, Scott M.

In: Journal of the American College of Cardiology, Vol. 64, No. 6, 12.08.2014, p. 601-612.

Research output: Contribution to journalArticle

@article{cfb2fb85f8ea4372bbb282cda4f1600a,
title = "2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol",
abstract = "The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines recently issued the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. This new guideline endorses a paradigm shift in strategies for reducing atherosclerotic cardiovascular disease (ASCVD) events by lowering blood cholesterol. Whereas previous guidelines focused on therapy to decrease low-density lipoprotein and non-high-density lipoprotein cholesterol to specific target levels, the new guideline instead proposes implementation of cholesterol-lowering treatment using evidenced-based intensity of statin therapy without such targets. The guideline also provides a new risk estimator for primary prevention decisions, including stroke outcomes and data on African Americans, which will significantly increase the number of patients recommended for outcome-related benefits of cholesterol-lowering therapy. The first section of this paper reviews the process by which the task force developed the new evidence-based guideline, the major findings and recommendations, and their implications. The second section primarily focuses on the question of how much low-density lipoprotein cholesterol should be lowered and on additional considerations in risk assessment.",
keywords = "atherosclerosis, cardiovascular diseases, cholesterol, hydroxymethylglutaryl- CoA reductase inhibitors, LDL, lipoproteins, risk assessment, risk factors",
author = "Smith, {Sidney C.} and Grundy, {Scott M}",
year = "2014",
month = "8",
day = "12",
doi = "10.1016/j.jacc.2014.06.1159",
language = "English (US)",
volume = "64",
pages = "601--612",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol

AU - Smith, Sidney C.

AU - Grundy, Scott M

PY - 2014/8/12

Y1 - 2014/8/12

N2 - The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines recently issued the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. This new guideline endorses a paradigm shift in strategies for reducing atherosclerotic cardiovascular disease (ASCVD) events by lowering blood cholesterol. Whereas previous guidelines focused on therapy to decrease low-density lipoprotein and non-high-density lipoprotein cholesterol to specific target levels, the new guideline instead proposes implementation of cholesterol-lowering treatment using evidenced-based intensity of statin therapy without such targets. The guideline also provides a new risk estimator for primary prevention decisions, including stroke outcomes and data on African Americans, which will significantly increase the number of patients recommended for outcome-related benefits of cholesterol-lowering therapy. The first section of this paper reviews the process by which the task force developed the new evidence-based guideline, the major findings and recommendations, and their implications. The second section primarily focuses on the question of how much low-density lipoprotein cholesterol should be lowered and on additional considerations in risk assessment.

AB - The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines recently issued the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. This new guideline endorses a paradigm shift in strategies for reducing atherosclerotic cardiovascular disease (ASCVD) events by lowering blood cholesterol. Whereas previous guidelines focused on therapy to decrease low-density lipoprotein and non-high-density lipoprotein cholesterol to specific target levels, the new guideline instead proposes implementation of cholesterol-lowering treatment using evidenced-based intensity of statin therapy without such targets. The guideline also provides a new risk estimator for primary prevention decisions, including stroke outcomes and data on African Americans, which will significantly increase the number of patients recommended for outcome-related benefits of cholesterol-lowering therapy. The first section of this paper reviews the process by which the task force developed the new evidence-based guideline, the major findings and recommendations, and their implications. The second section primarily focuses on the question of how much low-density lipoprotein cholesterol should be lowered and on additional considerations in risk assessment.

KW - atherosclerosis

KW - cardiovascular diseases

KW - cholesterol

KW - hydroxymethylglutaryl- CoA reductase inhibitors

KW - LDL

KW - lipoproteins

KW - risk assessment

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=84905709162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905709162&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2014.06.1159

DO - 10.1016/j.jacc.2014.06.1159

M3 - Article

C2 - 25104531

AN - SCOPUS:84905709162

VL - 64

SP - 601

EP - 612

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 6

ER -